# An Ipamorelin prescription can still be a no

A product page can describe an option. A clinician has to decide whether treatment makes sense for the person asking.

![A quiet stretch of grass between two adults independently arranging folding windbreaks.](/ipair-aebf7ac154be/room-for-questions.webp)

Room for a conversation, without a clinical setting or a patient depicted.

## Start with the person

What problem is being looked at? What would a useful improvement look like? Those questions come before choosing a combination. Wanting better sleep or more energy doesn’t by itself tell us what treatment fits.

Medical history matters to that discussion. FDA’s [ipamorelin assessment](https://www.fda.gov/media/182088/download) raises concerns about possible immune reactions and risks from raising growth hormone, including higher blood sugar. Long-term safety and safety in pregnancy aren’t established.

The conversation also needs room for alternatives, follow-up and deciding against treatment. A prescription can be the result of a review. It isn’t the result every request has to reach.

## Then name the preparation

CJC-1295 with DAC and without DAC are different ingredients. Plain ipamorelin and ipamorelin acetate, its salt form, are distinct too. FDA’s [CJC-1295 review](https://www.fda.gov/media/183819/download) and [ipamorelin review](https://www.fda.gov/media/182088/download) explain those differences.

A compounded medicine is made to meet particular needs. It isn’t FDA-approved: [FDA doesn’t check that it is safe, effective or well made before marketing](https://www.fda.gov/drugs/human-drug-compounding/compounding-and-fda-questions-and-answers). A prescription can’t supply that missing approval or evidence.

## Access and approval are different questions

Promise Peptides offers prescription review for CJC-1295 with ipamorelin through the [homepage invitation](/#invitation). A licensed U.S. clinician reviews each request and can decline it. Care is for U.S. patients, with state and treatment limits.

The FDA record needs its own space. On its [page current as of April 22, 2026](https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks), ipamorelin acetate is in Category 2 under the 503B policy for outsourcing facilities. Its nomination for 503A, the patient-specific pharmacy route, was withdrawn. CJC-1295 also appears in the withdrawn-nominations table.

The groups that asked for the ingredients to be considered withdrew their requests. That isn’t FDA clearance or permission to compound. FDA gives no individual withdrawal dates. A listed service doesn’t settle which preparation is lawful or appropriate.

## What could you ask?

Which exact ingredients are proposed, and why? What human evidence supports the hoped-for benefit? What alternatives are available, and how would problems be checked?

Those are conversation starters, not a test this page can pass for you. The [pairing guide](/with-cjc-1295) explains the evidence still missing for the combination. This is general information, with no personal medical or legal advice, and a product page can’t promise eligibility.

## Continue reading

[Read about the pair](/with-cjc-1295)

[Follow the sources](/references)

---

A guide for making sense of peptide pairings; we don’t run a clinic, a pharmacy or a shop.

[The CJC-1295 pairing](/with-cjc-1295)

[Research](/research)

[Sermorelin comparison](/vs-sermorelin)

[Effects](/effects)

[Dosage in studies](/dosage)

[Prescription questions](/prescription)

[Sources](/references)

[About](/about)

[Contact](/contact)

© 2026 Ipamorelin Pairings